Human CCL28 Antibody

Catalog #: MAB717
6 Citations Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB717
MAB717-SP

Chemotaxis Induced by CCL28 and Neutralization by Human CCL28 Antibody.

1 Image

All CCL28 Antibodies

Product Details

Citations (6)

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human CCL28 Antibody Summary

Species Reactivity

Human

Specificity

Detects human CCL28 in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant human CCL1, 2, 3, 4, 5, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, recombinant mouse CCL1, 2, 3, 4, 5, 6, 7, 9, 11, 19, 21, 22, 25, or recombinant rat CCL20 is observed.

Source

Monoclonal Mouse IgG₁ Clone # 62705

Purification

Protein A or G purified from ascites

Immunogen

E. coli-derived recombinant human CCL28
Ile23-Tyr127
Accession # Q9NRJ3

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Western Blot

1 µg/mL

Recombinant Human CCL28 (Catalog # 717-VC)

Neutralization

Measured by its ability to neutralize CCL28-induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with human CCR10. The Neutralization Dose (ND₅₀) is typically 15-45 µg/mL in the presence of 4 µg/mL Recombinant Human CCL28.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

Chemotaxis Induced by CCL28 and Neutralization by Human CCL28 Antibody. Recombinant Human CCL28 (Catalog # 717-VC) chemo-attracts the BaF3 mouse pro-B cell line transfected with human CCR10 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin. Chemotaxis elicited by Recombinant Human CCL28 (4 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human CCL28 Monoclonal Antibody (Catalog # MAB717). The ND₅₀ is typically 15-45 µg/mL.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CCL28

Human CCL28 (CC chemokine ligand 28) is a 127 amino acid (aa) precursor protein with a putative 22 aa signal peptide that is cleaved to produce the 105 aa residue mature protein. Mature human and mouse CCL28 share 83% aa sequence identity. Among CC chemokines, CCL28 shares the most homology with CCL27/CTACK. The mouse CCL28 gene has been mapped to the distal region of chromosome 13. Human and mouse CCL28 RNA expression is highest in epithelial cells of normal and pathologic colon. Human CCL28 RNA is also present in normal and asthmatic lung tissues. CCR10 (GPR2 orphan receptor) is the receptor for both CCL27/CTACK and CCL28.

References

Wang, W. et al. (2000) J. Biol. Chem. 275:22313.

Entrez Gene IDs

56477 (Human); 56838 (Mouse)

Alternate Names

CCL28; chemokine (C-C motif) ligand 28; MEC; member 28; MGC71902; Protein CCK1; VIC

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citations for Human CCL28 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

6 Citations: Showing 1 - 6
Filter your results:

Filter by:

Th22 cells are efficiently recruited in the gut by CCL28 as an alternative to CCL20 but do not compensate for the loss of Th17 cells in treated HIV-1-infected individuals
Authors: M Nayrac, M Requena, C Loiseau, M Cazabat, B Suc, N Carrere, K Barange, L Alric, G Martin-Blo, J Izopet, P Delobel
Mucosal Immunol, 2020-04-28;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Functional Assay
Brain-to-cervical lymph node signaling after stroke
Authors: E Esposito, BJ Ahn, J Shi, Y Nakamura, JH Park, ET Mandeville, Z Yu, SJ Chan, R Desai, A Hayakawa, X Ji, EH Lo, K Hayakawa
Nat Commun, 2019-11-22;10(1):5306.
Species: Mouse
Sample Types: CSF
Applications: Western Blot
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.
Authors: Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L, Coukos G
Nature, 2011-07-13;475(7355):226-30.
Species: Human
Sample Types: Whole Cells, Whole Tissue
Applications: IHC-Fr, Neutralization
Epithelial inflammation is associated with CCL28 production and the recruitment of regulatory T cells expressing CCR10.
Authors: Eksteen B, Miles A, Curbishley SM, Tselepis C, Grant AJ, Walker LS, Adams DH
J. Immunol., 2006-07-01;177(1):593-603.
Species: Human
Sample Types: Tissue Homogenates, Whole Tissue
Applications: IHC-P, Western Blot
CCL28 has dual roles in mucosal immunity as a chemokine with broad-spectrum antimicrobial activity.
Authors: Hieshima K, Ohtani H, Shibano M, Izawa D, Nakayama T, Kawasaki Y, Shiba F, Shiota M, Katou F, Saito T, Yoshie O
J. Immunol., 2003-02-01;170(3):1452-61.
Species: Human
Sample Types: Milk, Whole Tissue
Applications: ELISA Development, IHC-Fr
The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy.
Authors: Zsiros E, Duttagupta P, Dangaj D, Li H, Frank R, Garrabrant T, Hagemann I, Levine B, June C, Zhang L, Wang E, Marincola F, Bedognetti D, Powell D, Tanyi J, Feldman M, Kandalaft L, Coukos G
Clin Cancer Res, 2015-02-23;21(12):2840-50.